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Liver Organoid Assembly for Toxicity Assessment of Silver Nanoparticles	
Abstract 
Due to their interaction with water, 
n a n o p a r t i c l e s  e x p e r i e n c e  a 
compounding cycle of being absorbed 
in multiple organisms, most notably 
commercial fish and humans. The 
purpose of this research is to assemble 
clusters of hepatic cells to enable the 
assessment of the toxicity levels of silver 
nanoparticles (AgNPs). For this 
analysis, we cultured liver cancer cells 
(HepG2) into decellularized MSC 
matrices onto non-adherent surfaces to 
maintain cellular phenotype, increase 
cell proliferation, and promote high 
differentiation potential. Based on this 
research, spheroid MSC-DCM has 
shown to provide more physiologically 
relevant conditions to enhance the 
growth and detoxification activity of 
liver cancer cells. From this, we were 
able to quantitatively and qualitatively 
analyze the increased toxicity levels of 
AgNPs between size 40 and 130 nm.  	
Background 
Ø Nanoparticles (NPs) are being utilized 
for drug delivery.	
Ø Minimal degradation of NPs in the 
body lead to its release in the 
environment.	
Ø Accumulation in water can have 
negative impacts in wildlife and 
humans.	
Ø Ability to reach vital organs can elicit 
organ stress response such as 
symptoms of toxicity, genotoxicity, 
cytotoxicity, and inflammation.	
Ø S i l ve r n a n o p a r t i c l e s ( A g N P s ) 
primarily accumulate in the liver.	
Methodology   Results 
Conclusion 
•  Decellularized MSC spheroid matrices 
can be used for future studies focusing on 
liver cell metabolic functions.	
•  Larger nanoparticle diameter is less toxic, 
small diameter more so over time.	
•  Aggregation inhibits the entry of AgNPs 
into the cell. 	
Figure 10. Decellularization  schematic of  MSC cells grown 
on 2D surface.	
Figure 11. Decellularization  schematic of  MSC spheroids grown 
on non-adherent inSphero microwell. Scale bar: 100 µm	
Figure 1. Scanning electron microscopy images of 































Figure 2. Number of metabolically active HepG2 cells on 
different matrices conditions. Conditions such as NT represents 
the growth of HepG2 cells on non-adherent agarose gel without 
decellularized matrices. Sc DCM represents the growth of 
HepG2 cell on 2D MSC matrix. Sph DCM represents the 







Figure  6.  Metabolic  detoxification  activity  of  HepG2  cells 
assessed  via  Cytochrome  P450  detoxification  assay. 
Comparison between HepG2 cells  cultured on non-adherent 
surface  without  decellularized matrices,  decellularized MSC 
sheet  matrices,  and  decellularized  MSC  spheroid  matrices. 
Scale bar: 100 µm.  	
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Figure 7. Synthesized silver nanoparticle sizes of 40 nm 


















































30 ug/mL, 40 nm 
30 ug/mL, 130 nm 
60 ug/mL, 40 nm 
60 ug/mL, 130 nm 
Figure 9. Concentration (nmol) of urea produced by HepG2 only, 
dMSCs + HepG2 ± AgNPs from 0 hrs to 20 hrs.  	
Figure 8. Optical images of HepG2 cells cultured in 
decellularized MSCs (dMSCs). A) and B) HepG2 cells only with 
no silver nanoparticles (AgNPs); C) and D) dMSCs + HepG2 
cells with no AgNPs; E) and F) dMSCs and HepG2 with 30 µg/
mL and 40 nm diameter AgNPs; G) and H) dMSCs and HepG2 
with 30 µg/mL and 130 nm diameter AgNPs; I) and J) dMSCs 
and HepG2 with 60 µg/mL and 40 nm diameter AgNPs; K) and 
L) dMSCs and HepG2 with 60 µg/mL and 130 nm diameter 
AgNPs. Scale bar: 100 µm.  	
